Orion Group (ORN)
(Real Time Quote from BATS)
$7.80 USD
-0.22 (-2.74%)
Updated Apr 18, 2024 03:04 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ORN 7.80 -0.22(-2.74%)
Will ORN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ORN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORN
Orion Marine Group (ORN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Is Orion Group (ORN) Outperforming Other Construction Stocks This Year?
ORN: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Orion Marine (ORN) a Good Fit for 'Trend Investing'
Orion Marine (ORN) Soars 5.3%: Is Further Upside Left in the Stock?
Zacks Industry Outlook Highlights EMCOR, MasTec, Dycom Industries, Great Lakes Dredge & Dock and Orion
Other News for ORN
Orion Minerals Awaits Key Exploration Update
Orion Group Holdings, Inc. to Report First Quarter 2024 Financial Results on Wednesday, April 24
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
ORYZON to Provide Corporate Progress Updates at Several Events in April
Analysts Offer Insights on Industrial Goods Companies: Orion Group Holdings (ORN) and Boeing (BA)